drugset / Trial / NCT02466711

Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

NCT02466711 ↗

Phase 1 Completed 16 enrolled Motus Therapeutics, Inc. Mayo Clinic · collab
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the effects of relamorelin (RM-131) on gastric volume, motor and sensory effects in healthy patients.

Timeline

Start
2015-06
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Relamorelin Peptide 30 ug Subcutaneous